Chardan Capital initiated coverage on shares of Vascular Biogenics (NASDAQ:VBLT) in a research note published on Monday morning, The Fly reports. WaferGen Bio-systems, Inc. (WGBS) is now at $2.41 and volatility of 37.63% with a market cap of 019, a volume of 1,876,691 shares and a weekly performance of 112.42%.

Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Thursday, August 13th.

Vascular Biogenics Ltd. (VBLT) located in Israel has gained 9.67% per share today. During the year, the lowest price at which share is traded was $7.00 and hit the highest price at $8.37. The firm has a 50-day moving average of $5.45 and a 200 day moving average of $5.49.

09/22/2015- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the US stock market about the small and penny stocks, issues news alert on Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), Vascular Biogenics Ltd(NASDAQ:VBLT), Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG). The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04.

Several other research analysts have also recently issued reports on VBLT. Zacks lowered shares of Vascular Biogenics from a buy rating to a hold rating in a research report on Tuesday, May 26th. Roth Capital restated a buy rating on shares of Vascular Biogenics in a research report on Thursday, August 13th.

The three-day surge in the stock has pushed the market value to $196 million from $106 million. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The median price target for the stock at the current moment is at $16 which is seen as a huge positive. Vascular Biogenics Ltd are listed in the Health Care sector within NASDAQ. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The company on September 22 announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/446,505, titled “Compositions and Methods for the Prognosis and Treatment of Prostate Cancer”. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology.